ClinicalTrials.gg
RecruitingNCT05123482Updated Oct 13, 2026

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

A Phase 1/2 interventional study of AZD8205 and AZD8205 and AZD2936 (Rilvegostomig) in Breast Cancer, Biliary Tract Carcinoma and Ovarian Cancer, sponsored by AstraZeneca. Recruiting at 67 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years later.
Updated Oct 13, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Breast Neoplasms by AstraZeneca — 20 open to participants now, 50 under way, 24 of them phase 3. Breast Neoplasms · AstraZeneca.

Planned enrollment
31st of 125
460 · median 148
Started
2021
with 12 others
Phase 1/2
12 of 198
2 open now
Primary completion
2027-09
later than 29 of 49 live
Registered
148th of 198
by date

Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 31st largest by planned enrollment of the 125 interventional ones that give a count, is one of 13 that started in 2021, is one of 12 in phase 1/2, reaches primary completion later than 29 of the 49 other live ones, and was the 148th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 198 studies in Breast Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Breast Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

Read the detailed description

This study is a Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors

03

Conditions studied

  • Breast Cancer
  • Biliary Tract Carcinoma
  • Ovarian Cancer
  • Endometrial Cancer
  • Squamous Non-Small Cell Lung Cancer

Keywords

  • First In Human, antibody drug conjugate, cancer, solid tumour, Phase I, Phase IIa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria :

  • Age ≥ 18 years
  • / solid tumors treated with prior adequate standard of care therapy for tumor type and stage of disease or where in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerability to prior therapy.
  • per v1.1
  • (ECOG) Performance Status: 0-1
  • ≥ 12 weeks
  • Adequate bone marrow, hepatic, and renal function as defined in the protocol

Additional Inclusion Criteria For Sub-Study 1 Part A:

  • or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, BTC or endometrial cancer

Additional Inclusion Criteria For Sub-Study 1 Part B:

  • Histologically or cytologically confirmed metastatic or locally advanced and recurrent disease for the respective cohort:

    1. Cohort B1 (Biliary Tract Cancer)
    2. Cohort B2 (Ovarian Cancer)
    3. Cohort B3 (Breast Cancer)
    4. Cohort B4 (Endometrial Cancer)
    5. Cohort B5 (Squamous Non-Small Cell Lung Cancer)

      Additional Inclusion Criteria For Sub-Study 2 Part A:

  • Minimum body weight ≥ 30 kg.
  • Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, BTC, endometrial cancer or squamous non-small cell lung cancer.

Additional Inclusion Criteria For Sub-Study 3 Part A:

  • Minimum body weight ≥ 30 kg (for participants enrolled in cohorts including rilvegostomig only).
  • Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, BTC, endometrial cancer or squamous non-small cell lung cancer.

Additional Inclusion Criteria For Sub-Study 4 Part A:

  • Minimum body weight ≥ 30 kg (for participants enrolled in cohorts including rilvegostomig only).
  • Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, endometrial cancer or squamous non-small cell lung cancer.
  • Participants must have progressed following at least one but no more than 3 for metastatic or relapsed disease and have no satisfactory alternative treatment option as judged by the Investigator.

Key Exclusion Criteria:

  • Treatment with any of the following:

    1. Nitrosourea or mitomycin C within 6 weeks prior to the first dose of study treatment
    2. Any agents or study drugs from a previous clinical study within 5 half-lives or 28 days (whichever is shorter) prior to the first dose of study treatment
    3. Any other anticancer treatment within the following time periods prior to the first dose of study intervention:

      1. Cytotoxic treatment: 21 days
      2. Non-cytotoxic drugs: 21 days or 5 half-lives (whichever is shorter)
      3. Biological products including immuno-oncology agents: 28 days
  • Spinal cord compression or a history of .
  • unless treated, asymptomatic, stable, and not requiring continuous at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study.
  • Active infection including tuberculosis and , or
  • History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Participants with any of the following cardiac criteria:

    1. History of arrhythmia which is symptomatic or requires treatment ( v5.0 Grade 3); symptomatic or uncontrolled atrial fibrillation, or asymptomatic sustained ventricular tachycardia.
    2. Uncontrolled hypertension.
    3. Acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months.
    4. History of brain perfusion problems (eg, carotid stenosis) or stroke, or in the last 6 months prior to screening.
    5. Symptomatic heart failure ( class ≥ 2).
    6. Prior or current cardiomyopathy.
    7. Severe valvular heart disease.
    8. Mean resting > 470 msec.
    9. Risk factors for QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age.
  • Patients with history of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML (as determined by prior diagnostic investigation)

Additional Exclusion Criteria For Sub-Study 2 Part A:

  • Thromboembolic event within 3 months before the first dose of study intervention - No longer applicable per amendment 7
  • Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
  • Active or prior documented or inflammatory disorders requiring chronic treatment with steroids or other treatment.
  • History of organ transplant

Additional Exclusion Criteria For Sub-Study 2 Part B

  • Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)

Additional Exclusion Criteria For Sub-Study 3 Part A:

  • Concomitant use of medications or herbal supplements known to be strong cytochrome P (CYP) 3A4 inducers/inhibitors.
  • Any history of persisting (> 2 weeks) severe cytopenia due to any cause
  • Patients with any known predisposition to bleeding
  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of saruparib.
  • Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)

Additional Exclusion Criteria For Sub-Study 4 Part A:

  • Patients have received prior therapy with AZD9574 or more than 1 prior line of any other PARPi-based regimen
  • Concomitant use of medications or herbal supplements known to be strong cytochrome P (CYP) 3A4 inducers/inhibitors.
  • Previous treatment with rilvegostomig for the cohort treated with rilvegostomig
  • Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)
  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9574
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
460 participants (estimated)

Study arms

  • Experimental
    Sub-Study 1 AZD8205 Monotherapy

    Sub-Study 1 has two parts: Part A : The aim is to determine the safety, tolerability, Recommended Phase 2 Dose (RP2D), and/or the Maximum Tolerated Dose (MTD) of AZD8205. Part B: The aim of dose expansion is to evaluate anti-tumor activity of AZD8205 as monotherapy in select solid tumors.

    Drug: AZD8205

  • Experimental
    Sub Study 2: AZD8205 in combination with rilvegostomig

    Sub-Study 2 has two parts: Part A : Dose escalation to determine the safety, tolerability of AZD8205 + rilvegostomig Part B: Dose expansion to evaluate anti-tumor activity of AZD8205 + rilvegostomig in select solid tumors.

    Drug: AZD8205 and AZD2936 (Rilvegostomig)

  • Experimental
    Sub-Study 3 AZD8205 in combination with saruparib, with or without rilvegostomig

    Sub-Study 3 has two parts: Part A : Dose escalation to determine the safety, tolerability of AZD8205 + saruparib. Rilvegostomig may be added in a triplet combination once an AZD8205 + saruparib combination dose/schedule has been considered safe. Part B: Dose expansion to evaluate anti-tumor activity of AZD8205 + saruparib with or without rilvegostomig in select solid tumors.

    Drug: AZD8205 and AZD5305 (saruparib) · Drug: AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)

  • Experimental
    Sub-Study 4: AZD8205 in combination with AZD9574 with or without rilvegostomig (AZD2936)

    Sub-Study 4 has two parts: Part A : Dose escalation to determine the safety, tolerability of AZD8205 + AZD9574. Rilvegostomig may be added in a triplet combination once an AZD8205 + AZD9574 combination dose/schedule has been considered safe. Part B: may be added in the future depending on emerging data, following a formal protocol amendment.

    Drug: AZD8205 in combination with AZD9574 · Drug: AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)

Interventions

  • DrugAZD8205

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.

  • DrugAZD8205 and AZD2936 (Rilvegostomig)

    Drug page: Rilvegostomig

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

  • DrugAZD8205 and AZD5305 (saruparib)

    Drug page: AZD5305

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

  • DrugAZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)

    Drug page: AZD5305

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

  • DrugAZD8205 in combination with AZD9574

    Drug page: Palacaparib

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

  • DrugAZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)

    Drug page: Rilvegostomig

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

06

What researchers measure

Primary outcomes

  1. The number of patients with adverse events

    Number of patients with adverse events by system organ class and preferred term

    Time frame: From time of Informed consent to 30 days post last dose (approximately 1 year).

  2. The number of patients with serious adverse events

    Number of patients with serious adverse events by system organ class and preferred term

    Time frame: From time of Informed consent to 30 days post last dose (approximately 1 year)

  3. The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.

    A DLT is defined as any toxicity that occurs from the first dose of study treatment up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation and which includes pre-defined haematological and non-haematological toxicities.

    Time frame: From first dose of study treatment until the end of Cycle 1 (approximately 21 days).

  4. The number of patients with changes from baseline laboratory findings, ECGs and vital signs

    Description of laboratory findings and vital signs variables over time including change from baseline.

    Time frame: From time of informed consent to 30 days post last dose (approximately 1 year)

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1).

    Time frame: From first dose of AZD8205 to progressive disease or death in the absence of disease progression ( approx. 2 years )

  2. Duration of response (DoR)

    The time from the date of first response until date of disease progression (RECIST 1.1) or death in the absence of disease progression.

    Time frame: From the first documented response to confirmed progressive disease or death ( approx. 2 years )

  3. Progression free Survival (PFS)

    The time from first dose until RECIST 1.1 defined disease progression or cessation of study treatment.

    Time frame: From first dose of AZD8205 to progressive disease or death in the absence of disease progression ( approx. 2 years )

  4. Disease Control Rate at 12 weeks (DCR-12)

    Percentage of patients with confirmed CR or PR or having SD maintained for \>= 11 weeks from first dose (RECIST 1.1).

    Time frame: Measured from first dose until progression. For each patient, this is expected to be at 12 weeks

  5. Overall Survival (OS)

    The time from the date of the first dose of study treatment until death due to any cause.

    Time frame: From first dose of AZD8205 to death ( approx. 2 years )

  6. Pharmacokinetics of AZD8205: Area Under the concentration-time curve (AUC)

    Area under the plasma concentration-time curve

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 ( approx 2 years )

  7. Pharmacokinetics of AZD8205: Maximum plasma concentration of the study drug (Cmax)

    Maximum observed plasma concentration of the study drug

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 ( approx 2 years )

  8. Pharmacokinetics of AZD8205: Time to maximum plasma concentration of the study drug (T-max)

    Time to maximum observed plasma concentration of the study drug

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 ( approx 2 years )

  9. Pharmacokinetics of AZD8205: Clearance

    A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 ( approx 2 years )

  10. Pharmacokinetics of AZD8205: Terminal elimination half-life (t 1/2)

    Terminal elimination half life.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 ( approx 2 years )

  11. Immunogenicity of AZD8205.

    The number and percentage of participants who develop ADAs.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 ( approx 2 years )

  12. Sub Study 1: AZD8205 monotherapy Pharmacodynamics

    To assess the intratumoral pharmacodynamic biomarkers (gamma H2AX H-scores) to AZD8205 when administered as a monotherapy.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 ( approx 2 years )

  13. Sub Study 2: AZD8205 in combination with rilvegostomig Pharmacodynamics

    To assess the change in intratumoral pharmacodynamic biomarkers (gamma H2AX H-scores) to AZD8205 when administered in combination with rilvegostomig.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 ( approx 2 years )

  14. Sub-study 2: Rilvegostomig Pharmacokinetics when in combination with AZD8205

    To characterize the PK serum concentrations and PK parameters of rilvegostomig in combination with AZD8205.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 (approx 2 years)

  15. Sub-study 2: Immunogenicity of Rilvegostomig when in combination with AZD8205

    The number and percentage of participants who develop ADAs.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 (approx 2 years)

  16. Sub-Study 3: Pharmacokinetics of saruparib in combination with AZD8205 with or without rilvegostomig

    To characterize the PK plasma concentration and PK parameters of saruparib, including but not limited to AUC, Cmax, tmax, clearance, and half-life, as data allow, of saruparib when given in combination with AZD8205 with or without rilvegostomig.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 (approx 2 years)

  17. Sub-study 3: Pharmacokinetics of rilvegostomig in combination with AZD8205 and saruparib

    To characterize the PK serum concentrations and PK parameters (where applicable) of rilvegostomig when given in combination with AZD8205 and saruparib.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 (approx 2 years)

  18. Sub-Study 3: Immunogenicity of rilvegostomig in combination with AZD8205 and saruparib

    The number and percentage of participants who develop ADAs.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 (approx 2 years)

  19. Sub-Study 4: Pharmacokinetics of AZD9574 in combination with AZD8205 with or without rilvegostomig

    To characterize the PK plasma concentration and PK parameters of AZD9574, including but not limited to AUC, Cmax, tmax, clearance, and half-life, as data allow, of AZD9574 when given in combination with AZD8205 with or without rilvegostomig.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 (approx 2 years)

  20. Sub-study 4: Pharmacokinetics of rilvegostomig in combination with AZD8205 and AZD9574

    To characterize the PK serum concentrations and PK parameters (where applicable) of rilvegostomig when given in combination with AZD8205 and AZD9574.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 (approx 2 years)

  21. Sub-Study 4: Immunogenicity of rilvegostomig in combination with AZD8205 and AZD9574

    The number and percentage of participants who develop ADAs.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD8205 (approx 2 years)

07

Study locations

53 of 67 sites recruiting
  • Research Site
    Duarte, California 91010, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Irvine, California 92618, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Santa Monica, California 90404, United States
    Recruiting
  • Research Site
    Santa Rosa, California 95403, United States
    Recruiting
  • Research Site
    Shreveport, Louisiana 71103, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Baltimore, Maryland 21231, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Research Site
    Albuquerque, New Mexico 87109, United States
    Recruiting
  • Research Site
    Commack, New York 11725, United States
    Recruiting
  • Research Site
    New York, New York 10029, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Clayton, 3168, Australia
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Melbourne, VIC 3000, Australia
    Recruiting
  • Research Site
    Nedlands, 6009, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Anderlecht, 1070, Belgium
    Recruiting
  • Research Site
    Leuven, 3000, Belgium
    Recruiting
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Beijing, 100142, China
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Chongqing, 400030, China
    Recruiting
  • Research Site
    Guangzhou, 510060, China
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Kunming, 650118, China
    Recruiting
  • Research Site
    Shandong, China
    Recruiting
  • Research Site
    Budapest, 1062, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Budapest, 1082, Hungary
    Recruiting
  • Research Site
    Budapest, 1122, Hungary
    Recruiting
  • Research Site
    Milan, 20141, Italy
    Recruiting
  • Research Site
    Milan, 20159, Italy
    Recruiting
  • Research Site
    Modena, 41125, Italy
    Recruiting
  • Research Site
    Roma, 00168, Italy
    Recruiting
  • Research Site
    Chūōku, 104-0045, Japan
    Recruiting
  • Research Site
    Hidaka-shi, 350-1298, Japan
    Recruiting
  • Research Site
    Kashiwa, 277-8577, Japan
    Recruiting
  • Research Site
    Kōtoku, 135-8550, Japan
    Recruiting
  • Research Site
    Kurume-shi, 830-0011, Japan
    Recruiting
  • Research Site
    Sunto-gun, 411-8777, Japan
    Recruiting
  • Research Site
    Amsterdam, 1066 CX, Netherlands
    Recruiting
  • Research Site
    Gdansk, 80-214, Poland
    Recruiting
  • Research Site
    Warsaw, 02-781, Poland
    Recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 03722, South Korea
    Recruiting
  • Research Site
    Seoul, 05505, South Korea
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Recruiting
  • Research Site
    Barcelona, 8035, Spain
    Recruiting
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
    Recruiting
  • Research Site
    Madrid, 28027, Spain
    Recruiting
  • Research Site
    Málaga, 29010, Spain
    Recruiting
  • Research Site
    Pamplona, 31008, Spain
    Recruiting
  • Research Site
    Taichung, 40705, Taiwan
    Recruiting
  • Research Site
    Tainan, 704, Taiwan
    Recruiting
  • Research Site
    Taipei, 10002, Taiwan
    Recruiting
  • Research Site
    Taipei, 11259, Taiwan
    Recruiting
  • Research Site
    Taoyuan, 333, Taiwan
    Recruiting
  • Research Site
    Bangkok, 10330, Thailand
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Chiang Mai, 50200, Thailand
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Cambridge, CB2 0XY, United Kingdom
    Recruiting
  • Research Site
    Cardiff, CF14 2TL, United Kingdom
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    London, EC1A 7BE, United Kingdom
    Recruiting
08

References and documents

Publications

  • Huang Y, Tan HY, Yuan J, Mu R, Yang J, Ball K, Vijayakrishnan B, Masterson L, Kinneer K, Luheshi N, Liang M, Rosenbaum AI. Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability In Vivo. Anal Chem. 2024 Oct 22;96(42):16525-16533. doi: 10.1021/acs.analchem.4c02309. Epub 2024 Oct 11. PubMed 39392424 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Sep 2027, 71 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 71 months is above that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2021
First posted
Nov 17, 2021
StartActual
Oct 18, 2021
Primary completionEst.
Sep 29, 2027
CompletionEst.
Sep 29, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (1 now completed, 1 now active, not recruiting)
Show 2 sites
  • Research Site · Bangkok, ThailandRecruiting→Completed
  • Research Site · Chiang Mai, ThailandRecruiting→Active, not recruiting
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    2 sites changed recruiting status (1 now completed, 1 now active, not recruiting)
    Show 2 sites
    • Research Site · Bangkok, ThailandRecruiting→Completed
    • Research Site · Chiang Mai, ThailandRecruiting→Active, not recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05123482
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 17, 2021
Start date
Oct 18, 2021
Primary completion
Sep 29, 2027 (estimated)
Completion
Sep 29, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
AstraZeneca Breast Cancer Study Locator Service
Contact
az-bcsl@careboxhealth.com
1-877-400-4656

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rilvegostomig · AZD5305 · Palacaparib

Start the discussion